Received Feb 4, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | UNK | — |
| VARZOS | ZOSTER LIVE (ZOSTAVAX) | MERCK & CO. INC. | UNK | UNK | — |
Suspected vaccination failure; like shingles was starting; felt irritation in my intercostal rib area; pain; This serious case was reported by a consumer via interactive digital media and described the occurrence of vaccination failure in a patient who received Herpes zoster (Shingrix) for prophylaxis. Co-suspect products included Varicella zoster vaccine live (Oka/Merck) (Zostavax) for prophylaxis. On an unknown date, the patient received Shingrix and Zostavax. On an unknown date, an unknown time after receiving Shingrix and an unknown time after receiving Zostavax, the patient experienced vaccination failure (Verbatim: Suspected vaccination failure) (serious criteria GSK medically significant), shingles (Verbatim: like shingles was starting), skin irritation (Verbatim: felt irritation in my intercostal rib area) and pain (Verbatim: pain). The patient was treated with dimethyl sulfoxide. The outcome of the vaccination failure, shingles and skin irritation were not reported and the outcome of the pain was resolved (duration 1 hr). It was unknown if the reporter considered the vaccination failure, shingles, skin irritation and pain to be related to Shingrix. The company considered the vaccination failure to be unrelated to Shingrix. It was unknown if the company considered the shingles, skin irritation and pain to be related to Shingrix. Additional Information: GSK Receipt Date: 21-JAN-2026 This case was reported by a patient via interactive digital media. The patient had received both types of Shingles vaccines, due to adverse event patient applied DSMO (Dimethyl Sulfoxide) and the pain stopped in an hour. This case was considered as suspected vaccination failure as details regarding completion of primary schedule, time to onset for shingles and laboratory confirmation regarding shingles were unknown at the time of reporting. The batch number was not provided, and unable to contact the reporter.; Sender's Comments: A case of Vaccination failure, unknown time after receiving Shingrix and an unknown time after receiving Zostavax, in a patient. Based on the available information a?possible causality that the event was caused by the GSK product cannot be ascertained. Consent for further follow-up has not been received.